Zaltrap FDA Approval History
FDA Approved: Yes (First approved August 3, 2012)
Brand name: Zaltrap
Generic name: ziv-aflibercept
Dosage form: Injection
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: Colorectal Cancer
Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.
Development timeline for Zaltrap
|Aug 3, 2012||Approval FDA Approves Zaltrap for Metastatic Colorectal Cancer|
|Apr 5, 2012||Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap (aflibercept)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.